Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Technetium Tc99m Sestamibi · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Technetium Tc99m Sestamibi | DRUG | Rest and/or stress SPECT imaging study |
Inclusion Criteria: * Have been scheduled to undergo a clinically indicated rest or stress CARDIOLITE® MPI scan. * Be able to comply with imaging requirements permitting completion of rest or stress CARDIOLITE® whole-body scans and SPECT imaging procedures without the use of sedation. Exclusion Cr...
Technetium Tc99m Sestamibi is a small molecule radiopharmaceutical being studied for use in Kawasaki Disease. It is an investigational diagnostic agent intended to assess cardiac involvement in pediatric patients with this condition. The drug is currently in Phase 1 clinical development, meaning it is still being evaluated for safety and dosing.
Technetium Tc99m Sestamibi is a radiotracer that accumulates in myocardial tissue, allowing imaging of blood flow to the heart. In Kawasaki Disease, it is used to evaluate potential coronary artery abnormalities. The drug's mechanism relies on its uptake by cardiac cells, which can be visualized using nuclear imaging techniques.
Technetium Tc99m Sestamibi is developed by Lantheus Holdings, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol LNTH. The company is conducting clinical research to evaluate the drug's safety and efficacy in pediatric patients with Kawasaki Disease.
Technetium Tc99m Sestamibi is in Phase 1 clinical development for Kawasaki Disease. It is an investigational drug, meaning it has not been approved by regulatory authorities for this indication. The Phase 1 trial is complete, and the drug remains under investigation for potential future use.
Technetium Tc99m Sestamibi has one completed clinical trial, NCT00162045, titled 'A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects.' This Phase 1 study enrolled 79 participants with Kawasaki Disease across the United States, Canada, and Taiwan.
Yes, Technetium Tc99m Sestamibi is the same as CARDIOLITE, as indicated by the clinical trial title referencing CARDIOLITE®. The drug is also known by this brand name, which may be used interchangeably in research and clinical contexts.